This bill amends the Federal Food, Drug, and Cosmetic Act to change how the FDA enforces pediatric study requirements under section 505B. It formalizes a procedural path before enforcement—an explicit noncompliance letter followed by a 45‑day written response window and a due‑diligence determination—and restricts certain civil enforcement actions for products no longer marketed.
The bill also makes conforming adjustments to enforcement statutes and creates a 180‑day transition before aggressive enforcement can begin.
Separately, the bill alters how 505B treats orphan‑designated indications: FDA can exclude some orphan indications from 505B unless it determines pediatric assessments would provide meaningful therapeutic benefit, but it must issue guidance, hold a public meeting, and maintain public lists of diseases eligible for automatic full waivers. The package adds transparency requirements to FDA reporting on Pediatric Research Equity Act (PREA) enforcement, authorizes a small NIH funding set‑aside for pediatric research, and directs a GAO study on the impact of these changes on rare disease development and pediatric labeling.
At a Glance
What It Does
Requires FDA to issue a formal noncompliance letter and give sponsors 45 days to respond before concluding a failure to meet pediatric study obligations, and limits use of section 303 enforcement in specific cases (including products no longer marketed and during a 180‑day transition). It expands the statutory framework around orphan indications by allowing FDA to exclude certain orphan uses from 505B unless the agency finds pediatric assessments would be meaningfully beneficial, while mandating guidance, public meetings, and public waiver lists.
Who It Affects
Drug sponsors—especially companies developing orphan and rare‑disease therapies—and pediatric oncology developers face changes to pediatric‑study obligations and enforcement risk. FDA and NIH gain new reporting, guidance, and small funding‑allocation duties; pediatric clinicians and patient groups may see different pathways to pediatric labeling information.
Why It Matters
The bill shifts the compliance landscape from near‑automatic enforcement toward a documented process that can delay or limit penalties, while simultaneously adding new pathways and public‑facing lists that could change developers’ decisions about pediatric studies for orphan indications. That combination is likely to recalibrate incentives for rare‑disease drug development and the availability of pediatric evidence.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill rewrites the enforcement choreography for pediatric study requirements. Rather than moving quickly to civil penalties, FDA must first issue a titled noncompliance letter (the bill preserves the existing 270‑day marker in the statute as the trigger point but places that step in a labeled procedural box).
After the letter, the sponsor has 45 days to respond in writing. Only after FDA reviews that response and explicitly concludes the sponsor failed to show due diligence may it proceed to enforcement— and even then, civil actions under section 303 are limited when the product is no longer marketed.
The statute also includes a 180‑day transition window after enactment before section 303 enforcement for these failures may be used.
The bill modifies how orphan‑designated indications interact with the pediatric study statute. It makes 505B inapplicable to an orphan indication by default unless FDA decides pediatric assessments could provide a meaningful therapeutic benefit.
The agency must produce a draft guidance within a year of enactment and finalize it after a public meeting; the final rulemaking and guidance timetable control when the orphan‑provisions start to apply to new applications. The guidance must cover waiver criteria, how sponsors should use the pediatric study plan (PSP) mechanism for orphan indications, which rare diseases will be placed on automatic waiver lists, and how FDA will consider real‑world evidence and other alternative approaches.To increase public visibility the bill requires FDA to report detailed enforcement outcomes in its PREA reporting, including naming drugs, sponsors, and amounts for penalties, settlements, or payments tied to 505B failures.
The bill also authorizes NIH to redirect up to 1 percent of pediatric research allocations at each NIH institute or center for the specific pediatric research program identified in the statute for fiscal years 2026–2030. Finally, Congress directs GAO to evaluate the policy’s effects on rare disease drug development and pediatric labeling four years after the new orphan‑coverage rules become applicable; that review must include industry surveys and input from patient and provider groups.
Importantly, the bill expressly preserves FDA’s authority to require investigations of molecularly targeted pediatric cancer drugs that have orphan designation.
The Five Things You Need to Know
Before concluding a sponsor failed to meet a 505B pediatric requirement, FDA must send a noncompliance letter and give the sponsor 45 days to provide a written response; FDA then must determine whether the sponsor demonstrated due diligence.
Section 303 civil enforcement for failures under 505B can be used only if FDA finds lack of due diligence and generally will not be issued for drugs no longer marketed; enforcement for such failures is limited to events occurring 180 days after enactment.
The bill requires FDA’s PREA report to list every penalty, settlement, or payment under section 303 tied to 505B failures, including the drug name, sponsor, and amount.
NIH may allocate up to 1 percent of the pediatric research funds available to each institute or center for the pediatric studies program described in the Public Health Service Act for fiscal years 2026–2030.
FDA must maintain public 'automatic full waiver' lists for adult diseases/conditions where pediatric studies are impossible or meet full‑waiver criteria; if a disease appears on that list at the time of a sponsor’s initial pediatric study plan, the pediatric assessments for that disease are waived.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Formal noncompliance letter and limitations on enforcement
This amendment relabels the statutory trigger language to create a clear 'noncompliance letter' step in the timeline and clarifies the effect of noncompliance findings. The change narrows automatic penal exposure by stating a product no longer marketed should not be the target of section 303 enforcement for 505B failures. Practically, this forces FDA to document its compliance communications and reduces the agency’s ability to use criminal or civil tools against sponsors of withdrawn products.
45‑day response window and required due‑diligence review
The bill inserts an explicit 45‑day period for sponsors to respond to FDA’s noncompliance letter and requires FDA to review that written response before concluding a lack of due diligence. That creates a documented, stepwise administrative record that sponsors can use to demonstrate compliance efforts, and it raises the procedural bar for FDA to move immediately to enforcement.
180‑day transition before enforcement under section 303
Congress gives FDA a discrete clock: the agency may use section 303 for 505B failures only for failures occurring on or after 180 days after enactment. The provision is a statutory stay designed to allow FDA and sponsors time to adapt policies and procedures to the new due‑diligence requirement.
Expanded PREA reporting and penalty transparency
The bill expands the FDA’s statutory PREA report to include an evaluation of compliance with deferral deadlines and requires a public listing of penalties, settlements, or payments under section 303 for 505B failures, naming the drug, sponsor, and amount. This is a transparency mechanism intended to put enforcement outcomes on the public record and to allow external scrutiny of agency action.
NIH funding authorization for pediatric research program
NIH institutes and centers may make available up to 1 percent of their pediatric research allocations for the specific pediatric studies program named in the statute for each fiscal year from 2026 to 2030. This creates a small, time‑limited funding stream intended to support pediatric research activities that the bill prioritizes.
When 505B applies to orphan indications and rulemaking timetable
The bill makes 505B inapplicable by default to orphan‑designated indications unless FDA finds required pediatric assessments would offer meaningful therapeutic benefit. That change only applies to applications submitted after a defined applicability date (the later of 18 months after final guidance or a later date set by FDA). FDA must issue draft guidance within one year of enactment, hold a public meeting on that draft within six months, and finalize guidance within 18 months after the meeting.
Guidance content, GAO evaluation, and public waiver lists
The statute specifies guidance topics: how and when full and partial waivers for orphan indications will be granted, application of PSP timing and interactions with waivers, lists of rare diseases to add to automatic waiver lists and a process to update them, standards for accepting real‑world evidence for 505B obligations, and how to reconcile rare‑disease science with pediatric labeling needs. Congress also requires GAO to report four years after the applicability date on impacts to rare‑disease development and pediatric information availability, including industry surveys and stakeholder input. Finally, the bill mandates FDA maintain publicly posted automatic full‑waiver lists and ties a waiver to the PSP submission date when the disease is listed.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Sponsors of orphan and rare‑disease drugs — gain procedural protections (45‑day response and explicit due‑diligence review), clearer timelines for when orphan indications will be subject to 505B, and potential reductions in near‑term enforcement risk through the transition period.
- Small and mid‑sized biotech companies — benefit from greater predictability because the agency must publish waiver criteria and maintain public waiver lists, which can reduce regulatory uncertainty when choosing whether to pursue pediatric studies.
- NIH and pediatric research programs — receive a dedicated, though modest, authorization to use up to 1 percent of pediatric research allocations for programmatic pediatric studies funding across institutes for 2026–2030.
- Transparency and oversight stakeholders — patient groups, clinicians, and policy analysts gain access to a new line‑item reporting of 505B‑related penalties, settlements, and payments, enabling outside analysis of enforcement patterns.
- Pediatric patients (potentially) — stand to get more useful pediatric labeling over time if FDA uses the guidance and RWE paths to drive meaningful pediatric assessments rather than blanket waivers.
Who Bears the Cost
- FDA — takes on increased administrative work: drafting guidance, running a public meeting, maintaining and updating public waiver lists, expanding PREA reporting, and conducting more substantive case reviews under the new due‑diligence standard.
- Sponsors required to conduct pediatric studies — particularly smaller firms — may face material trial costs if FDA denies waivers and requires studies for orphan indications, increasing development expense and time to market.
- NIH institutes — effectively lose up to 1 percent of pediatric research allocations to the specific program designated by the bill, which is an opportunity cost against competing pediatric research priorities.
- Pediatric patients and clinicians — risk delayed enforcement action in cases of noncompliance because of the added procedural steps and the 180‑day transition, potentially slowing remedial action in some situations.
- Companies with publicized settlements or penalties — face reputational and commercial downside because the bill requires naming drugs, sponsors, and amounts in the PREA report.
Key Issues
The Core Tension
The central tension is between creating regulatory certainty and procedural protections for developers of rare‑disease drugs (to preserve incentives and lower the risk of costly pediatric trials) and ensuring that children receive timely, evidence‑based labeling and safeguards (which often requires mandating pediatric assessments that are costly and complex in small populations). The bill leans toward predictability for sponsors while layering in transparency and review mechanisms that aim—but may not be sufficient—to protect pediatric evidence generation.
The bill stitches two policy goals together—procedural protections for sponsors and new pathways for pediatric information in rare diseases—but those goals pull in different directions. Creating a documented 45‑day response window and a statutory 'due‑diligence' review raises the bar for FDA enforcement and gives sponsors time to produce evidence or remediation plans, which reduces the risk of precipitous penalties.
At the same time, statutory permission to exempt orphan indications from 505B unless FDA finds ‘meaningful therapeutic benefit’ concentrates a lot of discretion in the agency to decide when pediatric data are necessary. How FDA defines 'meaningful therapeutic benefit' will be decisive; the guidance requirement is intended to reduce uncertainty, but the statute leaves the criteria open and the timetable for applicability depends on FDA rulemaking and a public meeting.
Automatic waiver lists and a requirement that waivers be posted publicly create useful predictability, but the lists are blunt tools. If FDA errs on the side of inclusion, many orphan indications could escape pediatric assessment even where sparse pediatric data would have informed safe dosing or use.
Conversely, if FDA sets a narrow list, sponsors will face more frequent requirements for pediatric studies — a costly prospect in small patient populations. Operationally, FDA must also build capacity to review 45‑day responses, keep waiver lists updated, and publish penalty line items; those functions are resource‑intensive and the statute does not provide dedicated funding for the agency to carry them out.
Finally, timing matters. The 180‑day enforcement transition and the delayed applicability for orphan provisions mean the policy’s practical effects will phase in slowly.
The GAO review four years after the applicability date will provide useful retrospective analysis, but it will not resolve near‑term tradeoffs. The bill preserves FDA authority over molecularly targeted pediatric cancer investigations, which maintains a high‑priority exception but also seeds factual disputes about which products qualify as 'molecularly targeted'—an issue that could generate litigation or protracted agency determinations.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.